Astellas Pharma Inc.
4503.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥2,590 | ¥2,943 | ¥3,427 | ¥3,535 |
| - Cash | ¥188 | ¥336 | ¥377 | ¥316 |
| + Debt | ¥831 | ¥1,006 | ¥200 | ¥213 |
| Enterprise Value | ¥3,233 | ¥3,613 | ¥3,250 | ¥3,432 |
| Revenue | ¥1,912 | ¥1,604 | ¥1,519 | ¥1,296 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | ¥1,426 | ¥1,311 | ¥1,230 | ¥1,043 |
| % Margin | 74.6% | 81.8% | 81% | 80.5% |
| EBITDA | ¥248 | ¥195 | ¥240 | ¥241 |
| % Margin | 13% | 12.2% | 15.8% | 18.6% |
| Net Income | ¥51 | ¥17 | ¥99 | ¥124 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | ¥202 | ¥172 | ¥328 | ¥257 |
| Capital Expenditures | -¥37 | -¥82 | -¥89 | -¥76 |
| Free Cash Flow | ¥165 | ¥90 | ¥239 | ¥181 |